Collate Raises $95M in Funding at Almost $1 Billion Valuation

The company plans to use the funds to grow its engineering team, speed up product development, and expand sales to large pharmaceutical and medical device companies worldwide.

As AI transforms paperwork across industries, life sciences companies have become a key focus. These organizations handle large volumes of documents for regulatory filings, clinical trials, and product development, making them strong candidates for AI solutions. Collate entered the market at the right time—when AI technology had advanced enough to be effective. Still, many companies had already tried building their own systems and decided outsourcing was a better option, according to the company.

Since securing its first customer in May 2025, the San Francisco-based startup has added around 50 more clients, including major pharmaceutical companies, large medical device manufacturers, and publicly traded biotech firms. “We started working with some of the largest life sciences companies the same year we launched,” Sarna said. “Everyone is completely keyed into the problem.”

The paperwork in life sciences is both large and time-consuming. Some regulatory submissions can be up to 10,000 pages long and include huge amounts of clinical data, which AI can process much faster than humans.

Sarna says Collate helps save 50% to 90% of the time needed to complete these documents. Work that once took around seven months can now often be finished in a month or less. This is important because paperwork for clinical trials and regulatory filings often slows down the delivery of new treatments.

While AI can make mistakes or generate errors, Sarna says Collate’s accuracy is above 90% and often reaches about 97%. To ensure safety, the company also requires human review before any documents are exported. “That might not sound sexy, but it’s important,” she said. “I wanted to introduce AI and documentation to the industry in a way that I thought was patient-safe.”

Redpoint’s Satish Dharmaraj, who led the investment, says that he believes life sciences documentation could be an even larger opportunity than legal. “In the life sciences world, there are these big, big enterprise companies,” Dharmaraj says. “You will get a big pharma company and grow like a weed inside.”

Read More:FlackTek Appoints Dustin Becker as Director of Sales & Marketing

“Life sciences strategy and documentation are going to be the AI battleground of 2026, the same way they were for legal tech in 2025,” said Surbhi Sarna, CEO of Collate, drawing a parallel to the astronomical valuations seen by legal AI platforms like Harvey. “We timed our launch perfectly. We caught the market right as major life sciences firms realised that trying to build their own internal compliance LLMs from scratch was far too inefficient and complex. They needed an enterprise-grade vendor.”

About Collate

Founded by Surbhi Sarna, Nate Smith, and Jigish Patel, Collate builds large language model tools that help automate complex regulatory filings, clinical trial documents and product development paperwork. The system also includes human checks to ensure accuracy before anything is finalized.

Read More:Generalist AI Raises $400M in Funding at $2 Billion Valuation